What is William Blair’s Forecast for Insulet Q3 Earnings?

Insulet Co. (NASDAQ:PODD) – Analysts at William Blair boosted their Q3 2025 earnings estimates for shares of Insulet in a report issued on Monday, November 11th. William Blair analyst M. Andrew now expects that the medical instruments supplier will earn $1.04 per share for the quarter, up from their previous estimate of $0.97. The consensus estimate for Insulet’s current full-year earnings is $3.22 per share. William Blair also issued estimates for Insulet’s Q4 2025 earnings at $1.20 EPS.

A number of other research firms have also recently commented on PODD. BTIG Research lifted their target price on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Morgan Stanley lifted their price target on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Raymond James increased their price objective on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. Piper Sandler raised their target price on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Finally, Citigroup upped their price target on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research report on Tuesday, October 1st. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.27.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $260.12 on Thursday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet has a 12 month low of $160.19 and a 12 month high of $279.40. The firm has a market capitalization of $18.25 billion, a P/E ratio of 44.54, a P/E/G ratio of 4.11 and a beta of 1.22. The company’s fifty day moving average price is $237.77 and its 200 day moving average price is $207.47.

Institutional Investors Weigh In On Insulet

Hedge funds have recently added to or reduced their stakes in the company. Sei Investments Co. raised its stake in shares of Insulet by 16.2% during the 1st quarter. Sei Investments Co. now owns 11,782 shares of the medical instruments supplier’s stock worth $2,019,000 after buying an additional 1,639 shares in the last quarter. State Board of Administration of Florida Retirement System raised its position in Insulet by 3.8% in the first quarter. State Board of Administration of Florida Retirement System now owns 78,435 shares of the medical instruments supplier’s stock worth $13,444,000 after acquiring an additional 2,847 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Insulet by 22.3% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 78,391 shares of the medical instruments supplier’s stock valued at $13,436,000 after acquiring an additional 14,289 shares during the period. Mitsubishi UFJ Trust & Banking Corp boosted its position in shares of Insulet by 246.2% during the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 135,547 shares of the medical instruments supplier’s stock worth $23,168,000 after purchasing an additional 96,390 shares in the last quarter. Finally, Intech Investment Management LLC grew its stake in shares of Insulet by 113.8% during the 1st quarter. Intech Investment Management LLC now owns 6,649 shares of the medical instruments supplier’s stock worth $1,140,000 after purchasing an additional 3,539 shares during the period.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.